Codiak Biosciences Competitors and Similar CompaniesClear all

Codiak Biosciences's competitors and similar companies include Takeda and ArunA Bio.
Codiak Biosciences
Codiak Biosciences
Codiak Biosciences is a biopharmaceutical company focused on the development of exosome-based therapeutics.
Takeda
Takeda
Takeda Pharmaceutical (武田薬品工業株式会社) is a biopharmaceutical company engaged in the research, development, production, and commercialization of pharmaceutical products.
ArunA Bio
ArunA Bio
ArunA Bio is engaged in advancing a new class of cell-free biologics, exosomes, for the treatment of central nervous system (CNS) and neurodegenerative disorders and leveraging a platform to optimize the delivery of RNAs, antibodies, genes and small molecules.
Founding Date
Founding Date
2015
Founding Date
1781
Founding Date
2003
Type
Type
Public
Type
Public
Type
Private
Tags
Locations
Locations
Cambridge, US HQ
Locations
Tokyo, JP HQ
Buenos Aires, AR
The Rocks, AU
Linz, AT
Wien, AT
Wien, AT
Lessines, BE
see more
Locations
Athens, US HQ
Athens, US
Employees
Employees
992% decrease
Employees
47,4554% decrease
Employees
274% increase
Valuation ($)
Valuation ($)
2.8 m
Valuation ($)
43.7 b
Valuation ($)
N/A

Financial

Revenue (est.)
Revenue (est.)
$22.9m (FY, 2021)
Revenue (est.)
¥4.6t (FY, 2025)
Revenue (est.)
N/A
Net income
Net income
($37.2m) (FY, 2021)
Net income
¥108.1b (FY, 2025)
Net income
N/A

Operating

Phase II Trials Products
Phase II Trials Products
2 (Q2, 2020)
Phase II Trials Products
10 (May, 2025)
Phase II Trials Products
N/A

Funding

Total funding raised
Total funding raised
$ 168.5m
Total funding raised
$ 57.8m
Total funding raised
$ 26.9m
For sources of this data, please see the company profile

View Company Profiles

Takeda
HQ
Tokyo, JP
Employees
47,455↓ 4% decrease

Takeda Pharmaceutical (武田薬品工業株式会社) is a biopharmaceutical company engaged in the research, development, production, and commercialization of pharmaceutical products.

View company
ArunA Bio
HQ
Athens, US
Employees
27↑ 4% increase

ArunA Bio is engaged in advancing a new class of cell-free biologics, exosomes, for the treatment of central nervous system (CNS) and neurodegenerative disorders and leveraging a platform to optimize the delivery of RNAs, antibodies, genes and small molecules.

View company